![Paradoxical risk of reduced fertility after exposure of prepubertal mice to vincristine or cyclophosphamide at low gonadotoxic doses in humans | Scientific Reports Paradoxical risk of reduced fertility after exposure of prepubertal mice to vincristine or cyclophosphamide at low gonadotoxic doses in humans | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-020-74862-8/MediaObjects/41598_2020_74862_Fig1_HTML.png)
Paradoxical risk of reduced fertility after exposure of prepubertal mice to vincristine or cyclophosphamide at low gonadotoxic doses in humans | Scientific Reports
Cyclophosphamide: As bad as its reputation? Long-term single centre experience of cyclophosphamide side effects in the treatment
![Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial - The Lancet Respiratory Medicine Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial - The Lancet Respiratory Medicine](https://www.thelancet.com/cms/attachment/f9925654-2075-4af3-810f-b1d854511658/gr1_lrg.jpg)
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial - The Lancet Respiratory Medicine
![Safety of Cyclophosphamide Therapy in Autoimmune Rheumatic Diseases Subramanian R, Pathak H, Ravindran V - Indian J Rheumatol Safety of Cyclophosphamide Therapy in Autoimmune Rheumatic Diseases Subramanian R, Pathak H, Ravindran V - Indian J Rheumatol](https://www.indianjrheumatol.com/articles/2019/14/2/images/IndianJRheumatol_2019_14_2_127_257843_t3.jpg)
Safety of Cyclophosphamide Therapy in Autoimmune Rheumatic Diseases Subramanian R, Pathak H, Ravindran V - Indian J Rheumatol
![Chemotherapy and Biotherapy Agents. Objectives At the completion of this session the participant will be able to: ◦ Identify common side effects for individual. - ppt download Chemotherapy and Biotherapy Agents. Objectives At the completion of this session the participant will be able to: ◦ Identify common side effects for individual. - ppt download](https://images.slideplayer.com/16/4882231/slides/slide_4.jpg)
Chemotherapy and Biotherapy Agents. Objectives At the completion of this session the participant will be able to: ◦ Identify common side effects for individual. - ppt download
![Long-Term Outcome After Cyclophosphamide Treatment in Children With Steroid-Dependent and Frequently Relapsing Minimal Change Nephrotic Syndrome - ScienceDirect Long-Term Outcome After Cyclophosphamide Treatment in Children With Steroid-Dependent and Frequently Relapsing Minimal Change Nephrotic Syndrome - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0272638607005173-gr1.jpg)
Long-Term Outcome After Cyclophosphamide Treatment in Children With Steroid-Dependent and Frequently Relapsing Minimal Change Nephrotic Syndrome - ScienceDirect
![Frontiers | Cyclophosphamide Exposure Causes Long-Term Detrimental Effect of Oocytes Developmental Competence Through Affecting the Epigenetic Modification and Maternal Factors' Transcription During Oocyte Growth Frontiers | Cyclophosphamide Exposure Causes Long-Term Detrimental Effect of Oocytes Developmental Competence Through Affecting the Epigenetic Modification and Maternal Factors' Transcription During Oocyte Growth](https://www.frontiersin.org/files/Articles/682060/fcell-09-682060-HTML/image_m/fcell-09-682060-g001.jpg)
Frontiers | Cyclophosphamide Exposure Causes Long-Term Detrimental Effect of Oocytes Developmental Competence Through Affecting the Epigenetic Modification and Maternal Factors' Transcription During Oocyte Growth
![Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial - The Lancet Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial - The Lancet](https://www.thelancet.com/cms/attachment/2001011662/2003799460/gr1.gif)
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial - The Lancet
![Cyclophosphamide induced physiological and biochemical changes in mice with an emphasis on sensitivity analysis - ScienceDirect Cyclophosphamide induced physiological and biochemical changes in mice with an emphasis on sensitivity analysis - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0147651320317255-ga1.jpg)